The clinical efficacy of epristeride in the treatment of benign prostatic hyperplasia.
- Author:
Xiao-Bing JU
1
;
Hong-Fei WU
;
Li-Xin HUA
;
Wei ZHANG
;
Jie LI
Author Information
- Publication Type:Clinical Trial
- MeSH: Aged; Aged, 80 and over; Androstadienes; adverse effects; therapeutic use; Humans; Male; Middle Aged; Prostatic Hyperplasia; drug therapy; Treatment Outcome
- From: National Journal of Andrology 2002;8(1):42-44
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVESTo estimate the clinical safety, efficacy of Epristeride in the treatment of benign prostatic hyperplasia (BPH).
METHODSOne hundred and fourty-one BPH patients, aged from 50 to 83 years old [(66.18 +/- 6.41) yr], were given Epristeride tablets 5 mg p.o., twice daily for 120 days. To synthetically estimate the efficacy by the changing rate of international prostate symptom score (IPSS), maximum flow rate (Qmax), the volume of prostate (V) and the residual urine (Ru).
RESULTSThe total efficacy was 81.29%. The adverse reactions include 1 case (0.72%) of exanthem, 1 case (0.72%) of nausea and vomiting, 1 case (0.72%) of insomnia, 1 case (0.72%) of tinnitus and 3 cases (2.16%) of erectile dysfunction. Two patients discontinued the treatment due to the side effects (1.44%). There was no clinical significantly abnormal laboratory index during the treatment.
CONCLUSIONSEpristeride tablets was safe and effective in the treatment of BPH.
